Q2 FY2026 EarningsQ2 FY2026 results significantly beat consensus across the board, led by revenue of $132M (+15.74% vs. expected) and strong testing services demand. GAAP EPS reached $2.07, driven by a $113M gain from the Lab Products divestiture, while non-GAAP EPS of $0.37 outperformed the $0.232 consensus by 59.48%. Following the robust performance and the Naveris acquisition, management raised FY26 revenue guidance to $490M-$500M, well above previous ranges.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Caredex(CDNA) the Revenue is 131.95 M (+52.23%), Beat estimate;the EBIT is 113.22 M (+1118%), Beat estimate;the EPS is 2.07 (+1394%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.13B52.23%
0.11B31.58%
+0.02B20.65%
EBITExceed expectations
0.11B1118.10%
-0.00B78.04%
+0.12B1,040.06%
EPSExceed expectations
2.071393.75%
0.0225114.06%
+2.04751,279.69%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf